Determining the influence of molecular alterations on pharmacological responses in cancer cell lines from the omic perspective is the logical first step towards making oncology treatment for patients more effective, specific, and logical. Our established CellMiner (http://discover.nci.nih.gov/cellminer) and in development CellMinerCDB (https://discover.nci.nih.gov/cellminercdb/) web-applications provide high-quality, clean, and numerically extensive molecular and pharmacological data, providing a basis for making these types of assessments. CellMiner provides extensive data on the NCI-60 cancerous cell lines, Including are the most extensive set of both drug activity, and molecular data found for any of the databases. The substantial activity profiles are those generated by the high-quality efforts of the Developmental Therapeutics Program (https://dtp.cancer.gov). Included currently are activity data for 21,766 compounds, including 130 Food and Drug Administration (FDA)-approved, 75 clinical trial drugs, as well as molecular data including i) transcript expression for 25,683 genes, ii) genetic variants for 16,568 genes, iii) transcript expression for 360 microRNAs, iv) protein levels for 94 genes, v) DNA copy number (from aCGH) for 23,413 genes, and vi) DNA methylation levels for 17,559 genes. CellMinerCDB, while currently containing fewer output types of data and tools, does provides an interactive web-application that allows the exploration of the larger (~1,000) cell line databases. Included are i) Cancer Cell Line Encyclopedia (CCLE, http://www.broadinstitute.org/software/cprg/?q=node/11) from the Broad Institute of MIT and Harvard, ii) Cancer Therapeutics Response Portal (CTRP, https://portals.broadinstitute.org/ctrp/) from the Broad Institute of MIT, and iii) Genomics of Drug Sensitivity in Cancer (GDSC, http://www.cancerrxgene.org) from the Wellcome Trust Sanger and Massachusetts General Hospital. These databases each contain ~1000 cell lines, and so provide a broader spectrum of cancer types as well as greater numbers within the cancer types that overlap with the NCI-60 (cell lines). Descriptions of the data availability, retrieval, and web-application functionalities will be presented, including informative examples of data integration, and translational results. <!–EndFragment–>
Citation Format: William C. Reinhold, Margot Sunshine, Sudir Varma, Fathi Elloumi, Yves Pommier, M.D., Ph.D.. CellMiner and CellMiner Cross-Database (CDB) as a foundation for the exploration of pharmacogenomics through the use of cancerous cell-lines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2290.